Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mario Biglietto has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina Santoro

    Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy

    4 shared publications
  • Erminia Baldacci

    Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy

    4 shared publications
  • Antonio Chistolini

    Hematology, Department of Translational and Precision Medicine Sapienza University of Rome, Italy

    3 shared publications
  • Martina Gherardini

    Hematology, Department of Translational and Precision Medicine Sapienza University of Rome, Italy

    3 shared publications
  • Rosaria Mormile

    Sapienza University of Rome

    3 shared publications
  • Stefania Trasarti

    Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome - Italy

    3 shared publications

Latest Publications

  • Open Access

    PO005 | EXTENDED ANTICOAGULATION WITH DOACS IN PATIENTS AFFECTED BY HEMATOLOGIC MALIGNANCIES AND VENOUS THROMBOEMBOLISM: DOES LOW DOSE FIT ALL?

    by Mario Biglietto

    Background and Aims. Data on the extended treatment of venous thromboembolism (VTE) in the oncohematologic patients is lacking. The aim of our monocentric retrospective analysis was to evaluate the efficacy and safety in secondary prophylaxis of two different Direct Oral Anticoagulants (DOACs) treatment strategies (full-dose/low-dose) in onco-hematologic patients, based on the persistence of complete venous occlusion.Methods. We included adult oncohematologic patients with objectively confirmed VTE and at least 12 months of follow-up from the start of DOAC treatment. During the acute-phase of VTE treatment (first 3-6 months), the patients were treated with therapeutic dose of anticoagulants. In the extended therapy, the patients were treated with full-dose DOAC in case of persistent complete thrombosis and with low-dose DOAC in case of partial or complete vein recanalization and active cancer. Follow-up visits were scheduled every three months and included monitoring for bleeding (B-AEs) and thrombotic adverse events (T-AEs). Imaging with doppler ultrasound or computed tomography was performed every six months as per institutional policy, or earlier if recurrence was suspected. B-AEs were classified according to the ISTH criteria.Results. Patients’ characteristics and AEs are summarized in Table 1. Fourteen bleeding events (87.5%) occurred during full-dose treatment (1 major [severe metrorrhagia] and 13 CRNM) and 2 (12.5%) during low-dose treatment (1 major [cerebral hemorrhage], 1 CRNM). The 13 CRNM events during full-dose included 10 gastrointestinal bleedings, 1 epistaxis, 1 mild metrorrhagia and 1 hematuria associated with bladder catheter placement. The CRNM event during low-dose was a conjunctival bleeding. During extended phase, the incidence rates of B-AEs were 9.9 per 100 patient-years for full-dose therapy and 0.8 per 100 patient-years for low-dose therapy. Nine patients (6.1%) experienced recurrent thrombosis during extended therapy with DOACs, including 6 (66.7%) on full-dose and 3 (33.3%) on low-dose. During extended phase, the incidence rates of T-AEs were 4.3 versus 1.3 per 100 patient-years, respectively. During follow-up, five patients experienced a platelet count reduction between 50×109/L and 100×109/L, while none had counts below 50×109/L.Conclusions. Despite the indication bias inherent in this retrospective design, our findings suggest that in onco-hematologic patients, full-dose therapy may be appropriate for those with persistent complete venous occlusion due to a higher baseline risk of recurrence, which appears to remain significant over time: the higher incidence rate of T-AEs during full dose DOAC in the extended treatment could be accounted to a higher thrombotic risk associated with no vein recanalization. De-escalation to reduced-dose DOACs after vein recanalization appeared to reduce the incidence of bleeding events, particularly CRNM B-AEs.

  • Open Access

    PO115 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES

    by Mario Biglietto

    Background. Severe hemophilia A with inhibitors has been associated, in the “pre-emicizumab era”, with high bleeding risk and complex management. AL amyloidosis is a rare plasma cell dyscrasia characterized by monoclonal light chain deposition with systemic involvement. We report a case of AL amyloidosis in a patient with severe hemophilia A and high-titer inhibitors, who had a monozygotic twin.Case report. The patient and his monozygotic twin were referred to our center in 1973 at the age of 10 for severe hemophilia A; the proband had also a high-titer inhibitor, developed after repeated treatment with pdFVIII and blood components. He was subsequently managed with bypassing agents. Molecular analysis later identified a F8 splice-site mutation (c.1537+1G>A). In 1991, the patient tested positive for HCV with spontaneous viral clearance. In 1995, a first immune tolerance induction (ITI) attempt using the Malmö protocol failed. Thereafter the clinical course was complicated by multiple major bleeding events; nevertheless the patient repeatedly refused a new ITI course. After two iliopsoas hematomas, the first in 2010 and the second in 2014, he agreed to a second ITI course, initiated in July 2014 using pdFVIII/vWF concentrate (100 IU/kg/day). A transient inhibitor rise was observed, reaching a peak of 1715 BU after two weeks from ITI start. In August 2014 a severe episode of diffuse abdominal bleeding occurred, treated with large amount of rFVIIa in the emergency department. Thereafter, no further hemorrhagic events were reported, and the inhibitor titer progressively declined, reaching <1 BU in October 2016. Then, pdFVIII/vWF concentrate was tapered until reaching a dose of 40 IU/Kg/day in March 2017. In August 2014, during the hospitalization, laboratory investigations revealed an IgD-lambda monoclonal gammopathy, with a kappa/lambda free light chain ratio of 0.04 and urinary lambda Bence-Jones protein excretion of 195 mg/24 h. The patient was a physician and at that time declined further evaluation of the monoclonal gammopathy. Two years later, in August 2016, the patient was diagnosed with heart failure with reduced ejection fraction and concentric left ventricular hypertrophy. Cardiac magnetic resonance imaging was suggestive of transthyretin amyloidosis, although AL amyloidosis could not be excluded. A periumbilical fat biopsy confirmed AL amyloidosis diagnosis, and treatment with VCD (bortezomib, cyclophosphamide, and dexamethasone) was initiated. A few days after starting therapy, in April 2017, the patient died from sudden cardiac death. We report that the twin brother never developed an inhibitor and has a lambda monoclonal gammopathy without evidence of organ involvement. Finally, the last year he developed a cholangiocarcinoma.Conclusions. This case shows the rare coexistence of severe hemophilia A with inhibitors and AL amyloidosis in a monozygotic twin, whose brother did never develop an inhibitor. This suggests that genetic background alone is not sufficient to determine the inhibitor event. Moreover, as regards the AL amyloidosis, we could speculate if previous treatment with cyclophosphamide, but also the immune stimulation during ITI may have contributed to clonal progression; otherwise his twin brother without inhibitor present a stable monoclonal gammopathy and developed a cholangiocarcinoma. Environmental factors could have had an impact on these divergent clinical histories: same genes, different outcomes.

  • Open Access

    PO053 | PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY

    by Mario Biglietto

    Background and Aims. Multiple Myeloma (MM) is a plasma cell dyscrasia characterized by the clonal proliferation of plasma cells, which is associated with a significantly increased risk of both thrombotic and hemorrhagic complications. This ongoing prospective observational study aims to characterize platelet function and thrombin generation (TGA) in patients with newly diagnosed MM and to assess the impact of first-line therapy on these parameters.Methods. To date, eighteen patients with newly diagnosed MM have been enrolled. Platelet function was evaluated using closure time (PFA200) and light transmission aggregometry (Born method) with four agonists: ADP (5 µM), Epinephrine (Epi) (10 µM), Collagen (Coll) (2 µg/ml), and Arachidonic Acid (AA) (1 mM). Thrombin generation (TGA) was assessed using the Calibrated Automated Thrombogram (CAT) assay. Baseline results were compared with historical healthy control cohorts. Intra-patient analysis was performed on 11 patients after four cycles of induction therapy (D-VTd or DRd). Statistical analysis was performed using R software (version 4.4). Comparisons between patients and controls were performed using the Wilcoxon rank-sum test and Pearson’s Chi-square test. For paired data the Wilcoxon signed-rank test was employed. Statistical significance was set at p < 0.05.Results. In this interim analysis, at diagnosis, MM patients exhibited significantly lower platelet aggregation compared to controls for ADP (p=0.008), Epinephrine (p=0.004), and Arachidonic Acid (p=0.026). Procoagulant markers were significantly elevated: vWF:Ag (p=0.002) and vWF:RCo (p=0.009), while Factor VIII (p=0.065) showed a trend toward elevation. TGA analysis revealed significantly prolonged Lag Time (p=0.021) and significantly higher ETP (p=0.009), Peak (p=0.003), and Velocity Index (p=0.014) in MM patients (Table 1). Following therapy, most parameters remained stable, showing persistence of high thrombin generation, elevated vWF/FVIII levels, and impaired platelet function. Only Mean Platelet Volume (MPV) showed a significant decrease (7.85 fl vs. 7.30 fl, p=0.024).Conclusions. This study highlights the coexistence of hypercoagulability and platelet dysfunction in MM. Based on these preliminary results, the reduction of tumor burden and the treatment do not seem to modify the evaluated parameters.

  • Open Access

    CO063 | NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A POTENTIAL PREDICTOR OF THROMBOSIS IN CLASSICAL HODGKIN LYMPHOMA: AN EXPLORATORY ANALYSIS

    by Mario Biglietto

    Background and Aims. The neutrophil-to-lymphocyte ratio (NLR) is a simple inflammatory biomarker associated with prognosis and cancer-associated thrombosis (CAT). This study aimed to evaluate NLR as a predictor of CAT in patients with classic Hodgkin lymphoma (cHL).Methods. We retrospectively evaluated adult patients (>18 years) diagnosed and treated for cHL between 2017 and 2020 at our institution and included in the “Thro-HL” multicenter study. Patients receiving anticoagulation for any indication were excluded. All suspected thrombotic events (TE) were confirmed by imaging. Thrombotic event-free survival (t-EFS) was defined as the time from diagnosis to the occurrence of thrombosis or last follow-up. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal NLR cut-off for predicting TE. Associations between dichotomized NLR, established clinical risk scores (Khorana, Throly, and Thro-HL), and TE were assessed using Pearson’s chi-square test. Time-to-event analyses were performed using Cox proportional hazards regression. A multivariable backward stepwise Cox model was used to assess the independent predictive value of NLR beyond clinical scores. Statistical significance was set at p3.9 as the optimal cut-off for predicting TE (AUC 0.633; sensitivity 72.2%; specificity 54.3%). In univariate analysis, elevated NLR (p=0.045), Khorana score (p=0.046), Throly score (p=0.01), and Thro-HL score (p=0.008) were all significantly associated with TE. In univariate Cox regression, the Khorana high-risk category was associated with increased risk compared with intermediate risk (HR 2.99, 95% CI 1.03–8.62, p=0.043). The Throly score showed an overall significant association (p=0.015), with a non-significant trend for high-risk patients (HR 6.96, 95% CI 0.87–55.69, p=0.067). The Thro-HL score demonstrated a strong association with thrombosis (p=0.010), with significantly higher risk in the high-risk group (HR 7.33, 95% CI 1.94–27.67, p=0.003). NLR > 3.9 was associated with a trend toward increased risk (HR 2.62, 95% CI 0.93–7.35, p = 0.067). In multivariable analysis, only the Thro-HL score remained independently associated with thrombotic risk, while NLR and the other scores were not retained.Conclusions. NLR showed a trend toward association with CAT in cHL, but it was not independently predictive after adjustment for established clinical risk models. Yet it should be assessed in larger cohorts to determine whether NLR may complement existing tools for thrombotic risk stratification in this population.

  • Open Access

    CO092 | FOSTAMATINIB IN CHRONIC IMMUNE THROMBOCYTOPENIA: A REAL-WORLD MONOCENTRIC EXPERIENCE

    by Mario Biglietto

    Background and aims. Fostamatinib, an inhibitor of spleen tyrosine kinase, has become a valuable therapeutic option for chronic ITP as a second or subsequent line of treatment. Our analysis aims to evaluate its efficacy and safety in the real-world setting.Methods. We retrospectively analyzed 43 consecutive adult patients (> 18 years) with chronic ITP treated with fostamatinib in our center. Efficacy was evaluated as time to treatment failure (TTF); data were censored for patients who did not relapse until the last follow-up or who discontinued treatment for reasons other than loss of efficacy. Clinical response was categorized according to the international consensus criteria by Rodeghiero et al. (2009). Safety was assessed by monitoring treatment-emergent adverse events, with a focus on infections, arterial hypertension, diarrhea, and thrombotic events. Infections were defined severe if they required hospitalization. Patients were stratified by therapy line in Group 1 (1-2 prior treatment lines) and Group 2 (> 3 prior treatment lines). Statistical analysis was performed with SPSS26 using Kaplan-Meier curves and the log-rank test. Statistical significance was set at p <0.05.Results. Thirty patients (69.8%) were female, and 13 (30.2%) were male. Prior to fostamatinib, patients had received a median of 4 therapy lines (range 2-12). All patients had been previously treated with corticosteroids (100%), while 21 (48.8%) received eltrombopag, 15 (34.9%) rituximab, 13 (30.2%) romiplostim, 8 (18.6%) avatrombopag, 6 (14.0%) splenectomy, 5 (11.6%) azathioprine, and 1 (2.3%) cyclosporine A. Twenty-three patients (53.4%) had a concomitant autoimmune diathesis, including Hashimoto thyroiditis (18.6%), persistent antiphospholipid antibody positivity (9.3%), antiphospholipid syndrome (7%), systemic lupus erythematosus (7%), multiple sclerosis (4.7%), common variable immunodeficiency (2.3%), Crohn's disease (2.3%), and Raynaud phenomenon (2.3%). Seven patients (16.3%) had previous thrombosis. Median age at fostamatinib start was 55 years (range 25-80). The median duration of fostamatinib treatment was 282 days (range 26-1319). The overall response rate (ORR) was 90.7%, with a complete response rate (CR) of 67.4%. Thirty-five patients (81.4%) received concomitant ITP treatments (15 corticosteroids, 12 TPO-RAs+corticosteroids, 6 TPO-RAs, and 2 rituximab+corticosteroids). Twelve patients (27.9%) discontinued fostamatinib due to non-response or loss of response, and two patients (4.7%) due to diarrhea; one patient (2.3%) tapered and discontinued fostamatinib, maintaining a response to therapy. No patients discontinued treatment due to arterial hypertension. No thrombotic events were reported. Severe infections occurred in 2 patients (4.7%), none of which led to permanent drug discontinuation. Kaplan-Meier analysis showed that therapy line is a significant predictor of response durability. Patients in Group 1 achieved a significantly longer median TTF compared to Group 2 (not reached vs. 112 days) (log-rank p=0.026) (Figure 1).Conclusions. Fostamatinib proved to be safe and effective in our monocentric experience with a median follow-up of about 10 months (16/43 patients with a drug exposure of more than a year). The use of fostamatinib as a second/third line of treatment led to a significantly more durable response, supporting its early use in the ITP treatment algorithm.

  • Open Access

    CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY

    by Mario Biglietto

    Background and Aims. The presence of antiphospholipid antibodies (aPL) and exposure to thrombopoietin receptor agonists (TPO-RAs) may increase thrombotic risk in patients with immune thrombocytopenia (ITP). This study aimed to identify predictors of thrombotic events (TEs) in ITP patients with persistent aPL positivity.Methods. We conducted a retrospective observational study including 56 consecutive ITP patients with persistent aPL positivity. Clinical, laboratory, and treatment data were collected. aPL testing included lupus anticoagulant (LA), anticardiolipin (aCL) IgG/IgM, and anti-β2 glycoprotein I (aβ2GPI) IgG/IgM. A high-risk aPL profile was defined according to ACR/EULAR 2023 criteria (LA positivity, high-titer single positivity, or double/triple positivity). Thrombosis-free survival (t-EFS) was defined as the time from ITP diagnosis to the first thrombotic event or last follow-up. Statistical analyses included univariate and multivariate logistic regression to identify predictors of thrombosis. Time-to-event analysis was performed using the Kaplan–Meier method, censoring patients without events at last follow-up. Odds ratios (OR), adjusted ORs (aOR), and 95% confidence intervals (CI) were calculated. A p-value <0.05 was considered statistically significant.Results. Median age at diagnosis was 37 years (range 10–81); 44 patients (78.6%) were female. All patients were persistently aPL-positive: 32 (57.1%) had single positivity, 16 (28.6%) double, and 8 (14.3%) triple positivity. A high-risk aPL profile was observed in 47 patients (83.9%), of whom 26 (55.3%) received primary antithrombotic prophylaxis (low-dose aspirin or clopidogrel). Twenty patients (35.7%) had concomitant autoimmune diseases, and 32 (57.1%) had cardiovascular comorbidities. Antirheumatic therapy was administered in 24 patients (42.9%), mainly hydroxychloroquine. Fifteen patients (26.8%) experienced a total of 20 thrombotic events: 12 venous and 4 arterial. The median platelet count at thrombosis was 72,000/µL (range 30,000–298,000). Eleven patients (19.6%) received TPO-RAs; among them, 6 (54.5%) developed venous thromboembolism (VTE) during treatment, corresponding to an incidence rate of 15.6 events per 100 patient-years. Kaplan–Meier analysis showed significantly reduced thrombosis-free survival in patients exposed to TPO-RAs (p=0.032). In univariate analysis, TPO-RA exposure was associated with increased thrombotic risk (OR 6.94; 95% CI 1.58–30.43; p=0.01), whereas antiplatelet prophylaxis (OR 0.20; 95% CI 0.048–0.799; p=0.02) and female sex (OR 0.26; 95% CI 0.07–0.99; p=0.048) were protective. In multivariate analysis, TPO-RA exposure remained an independent risk factor (aOR 6.98; 95% CI 1.36–35.78; p=0.02), while antiplatelet therapy retained a protective effect (aOR 0.20; 95% CI 0.04–0.97; p=0.046). Female sex was no longer significant (p=0.42). Other variables, including age, aGAPSS score, and aPL profile, were not associated with thrombosis.Conclusions. TPO-RA therapy appears to significantly increase the risk of VTE in ITP patients with persistent aPL positivity, whereas antiplatelet prophylaxis may reduce this risk. These findings support systematic aPL screening at ITP diagnosis and careful risk assessment before initiating TPO-RA therapy. Prospective studies are warranted to confirm these results.

  • Open Access

    CO-67 | CONGENITAL DYSFIBRINOGENEMIA: BLEEDING PHENOTYPE, THROMBOTIC COMPLICATIONS, AND LONG-TERM MANAGEMENT IN A MULTICENTER COHORT

    by Mario Biglietto

    Background and Aims. Congenital dysfibrinogenemia is a disorder caused by structural abnormalities of the fibrinogen molecule, resulting in impaired fibrinogen function. While most patients remain asymptomatic, some may present with bleeding manifestations and/or an increased risk of thrombosis. This multicenter study aims to describe the clinical phenotype of a cohort of patients with congenital dysfibrinogenemia.Materials and Methods. Patients diagnosed with congenital dysfibrinogenemia as per ISTH communication (Casini A., 2018) between 1992 and 2025 at different hemophilia centers affiliated with the Italian Association of Hemophilia Centers (AICE) were included. Bleedings were classified as per ISTH classification (Schulman S., 2005; Kaatz S., 2015) as minor, clinically relevant non-major (CRNM), and major.Results. Patients’ characteristics are summarized in Table 1. One-hundred and ten patients were included, 64 females and 46 males. Median follow-up is 4.7 years (0.1-30.1). Three patients presented with a thrombotic phenotype. The ISTH-BAT score at diagnosis was suggestive of bleeding disorder in 4 patients, normal in 89, and not available in 17. During follow-up no changes in ISTH-BAT score were observed. Thirty-two patients experienced at least one CRNM bleeding in their lives, and two patients experienced major bleedings following sleeve gastrectomy and hip replacement surgeries. Three patients experienced one venous thrombotic event and one other an arterial one. No patient received long-term anti-hemorrhagic prophylaxis. Seventy-nine subjects underwent 173 surgeries, of whom 13 were performed with antihemorrhagic prophylaxis using either tranexamic acid, fibrinogen concentrate, or fresh frozen plasma. Eight surgeries were complicated by CRNM bleedings and 2 by major bleedings. Major bleedings were managed only with red blood cell transfusions. Twenty-eight women underwent 51 pregnancies. No woman received either antithrombotic or anti-hemorrhagic prophylaxis during pregnancy. Forty-two pregnancies were carried to term. Seven miscarriages occurred, and two voluntary abortions were performed. Two patients received prophylactic enoxaparin in the puerperium, and three received anti-hemorrhagic prophylaxis at delivery: one with tranexamic acid, one with fibrinogen concentrate, and one with fresh frozen plasma. No pregnancy was complicated by hemorrhagic or thrombotic complications.Conclusions. In this cohort, dysfibrinogenemic patients showed a mild and heterogeneous clinical phenotype, with most subjects remaining asymptomatic. Pregnancy and surgical procedures were generally undertaken without complications, even in the absence of antihemorrhagic prophylaxis. Overall, these findings support a conservative and individualized management approach.

  • Open Access

    CO-30 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES

    by Mario Biglietto

    Background. Severe hemophilia A with inhibitors has been associated, in the “pre-emicizumab era," with high bleeding risk and complex management. AL amyloidosis is a rare plasma cell dyscrasia characterized by monoclonal light chain deposition with systemic involvement. We report a case of AL amyloidosis in a patient with severe hemophilia A and high-titer inhibitors, who had a monozygotic twin.Case Report. The patient and his monozygotic twin were referred to our center in 1973 at the age of 10 for severe hemophilia A; the proband had developed high-titer inhibitor after repeated exposure to pdFVIII and blood products and was subsequently treated with bypassing agents. Molecular analysis identified the F8 splice-site mutation c.1537+1G>A. In 1991 he tested positive for HCV, with spontaneous viral clearance. In 1995, a first immune tolerance induction (ITI) attempt with the Malmö protocol failed. The following years were complicated by multiple bleeding episodes, but the patient repeatedly refused a second ITI course. After two iliopsoas hematomas in 2010 and 2014, he agreed to a second ITI course with pdFVIII/vWF concentrate (100 IU/kg/day), started in July 2014. A transient inhibitor increase occurred, peaking at 1715 BU after two weeks. In August 2014 he experienced severe diffuse abdominal bleeding requiring large amounts of rFVIIa. Subsequently, no further bleeding events occurred, and the inhibitor progressively declined to <1 BU in October 2016; pdFVIII/vWF was then tapered to 40 IU/kg/day by March 2017. During the 2014 hospitalization, laboratory tests revealed IgD-λ monoclonal gammopathy, with a κ/λ ratio of 0.04 and urinary λ Bence-Jones proteinuria of 195 mg/24 h. The patient declined further evaluation. In August 2016 he developed heart failure with reduced ejection fraction and concentric left ventricular hypertrophy. Periumbilical fat biopsy confirmed AL amyloidosis, and treatment with bortezomib, cyclophosphamide, and dexamethasone was started. In April 2017, a few days after treatment initiation, the patient died from sudden cardiac death. The monozygotic twin never developed inhibitors and presented only a stable lambda monoclonal gammopathy without organ involvement; he later developed cholangiocarcinoma.Conclusions. We describe the rare coexistence of severe hemophilia A with inhibitors and AL amyloidosis in a monozygotic twin whose brother never developed inhibitors, suggesting that genetic background alone is insufficient to explain inhibitor development. Our question has remained if previous cyclophosphamide exposure and immune stimulation during ITI may have contributed to clonal progression. Environmental factors may therefore have influenced these divergent clinical histories: same genes, different outcomes.

  • Open Access

    CO-70 | CONGENITAL AFIBRINOGENEMIA: BLEEDING PHENOTYPE, THROMBOTIC COMPLICATIONS, AND LONG-TERM MANAGEMENT IN A MULTICENTER COHORT

    by Mario Biglietto

    Background and Aims. Congenital afibrinogenemia is characterized by severe bleedings and high thrombotic risk. Due to its rarity, there are no evidence-based strategies for the management of these patients. This multicentric experience aims to describe the phenotype of a cohort of afibrinogenemic patients.Materials and Methods. Patients diagnosed with congenital afibrinogenemia as per ISTH communication (Casini A., 2018) between 1970 and 2025 at different hemophilia centers affiliated with the Italian Association of Hemophilia Centers (AICE) were included. Bleedings were classified as per ISTH classification (Schulman S., 2005; Kaatz S., 2015) as minor, clinically relevant non-major (CRNM), or major; surgeries were classified as major and minor based on ESA consensus (Martin D., 2020).Results. Patients’ characteristics are summarized in Table 1. Ten patients were included, 6 females and 4 males. Median follow-up is 19 years (0.1-55). Five patients presented with a bleeding phenotype and five with a bleeding and thrombotic phenotype. The ISTH-BAT score at diagnosis was suggestive of a bleeding disorder in 8 patients, normal in 1, and not available in 1. During follow-up, ISTH-BAT score increased in 5/8 patients. All patients experienced at least one CRNM bleeding in their life, and half of them a major hemorrhage. Two patients experienced at least one venous thrombotic event, 2 an arterial one, and 1 both: 3 events occurred during fibrinogen concentrate administration. Five patients are receiving long-term anti-hemorrhagic prophylaxis, 4 with fibrinogen concentrate and 1 with fresh frozen plasma. The median age at prophylaxis start was 15 years (0.1-39) with a median duration of prophylaxis of 17 years (5-22). The reason for prophylaxis start was cerebral hemorrhage in 2 patients, hematemesis and frequent bleeding in 2, and arterial thrombosis of the left lower limb that needed amputation and lifelong dual antiplatelet prophylaxis in 1. During prophylaxis only one patient experienced bleeding diathesis, in particular epistaxis and muscular hematomas. Five patients underwent at least one major surgery: a post-traumatic splenectomy was complicated by massive portal vein thrombosis. No woman underwent pregnancy.Conclusions. In our cohort of 10 patients, all experienced at least one CRNM bleeding, and 5 major hemorrhages occurred. Thrombotic events occurred in half of the cohort. This confirms the dual nature of the disease, with an increased bleeding and thrombotic risk. Long-term prophylaxis was frequently required and initiated at a young age, mainly following life-threatening bleeding episodes or thrombotic complications. These findings highlight the complexity of clinical management in congenital afibrinogenemia and the need for individualized therapeutic strategies.

  • Open Access

    Procoagulant platelets mediate cerebral arterial thrombosis in cancer

    by Manuela De Michele, Paolo Amisano, Lucia Bertuccini, Francesca Spadaro, Francesca Iosi, Maria Carollo, Paola Piscopo, Elisabetta Straface, Lucrezia Gambardella, Mario Biglietto, et al.

    Cancer is associated with a systemic hypercoagulable state and an increased risk of acute ischemic stroke (AIS), yet the mechanisms underlying cancer-associated arterial thrombosis remain poorly defined. We conducted comprehensive analyses of blood and thrombi in patients with AIS and Cancer (AIS-Cancer), AIS without cancer, and cancer without AIS. AIS-Cancer showed the highest neutrophil activation, whereas biomarkers of systemic inflammation, endothelial dysfunction, and peripheral platelet phenotypes (proaggregant and procoagulant platelets and AV+ platelet-derived microvesicles) were similar across groups. In contrast, thrombi retrieved from large vessels in AIS-Cancer were predominantly platelet-rich and contained fibrin, neutrophils and neutrophil extracellular traps, whereas thrombi from non-cancer AIS were mainly red blood cell-rich. Platelets within AIS-Cancer thrombi exhibited a distinct procoagulant phenotype elicited in vitro with plasma from affected patients. Together, these findings suggest that cancer reprograms arterial thrombus formation toward a procoagulant and NET-rich phenotype, providing a rationale for therapies targeting procoagulant platelet activity in cancer-associated stroke.